{{Drugbox
| verifiedrevid = 464375666
| IUPAC_name = 2-(diethylamino)ethyl 3-amino-4-propoxybenzoate
| image = Proxymetacaine_structure.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|proxymetacaine}}
| pregnancy_US = C
| routes_of_administration = [[Topical]] ([[eye drop]]s)
<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism = Plasma
<!--Identifiers-->
| IUPHAR_ligand = 7283
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 499-67-2
| CAS_supplemental = <br>{{CAS|5875-06-9}} ([[hydrochloride|HCl]])
| ATC_prefix = S01
| ATC_suffix = HA04
| PubChem = 4935
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00807
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4766
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = B4OB0JHI1X
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08448
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1196
<!--Chemical data-->
| C=16 | H=26 | N=2 | O=3
| molecular_weight = 294.389 g/mol
| smiles = O=C(OCCN(CC)CC)c1ccc(OCCC)c(c1)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KCLANYCVBBTKTO-UHFFFAOYSA-N
}}
'''Proxymetacaine''' ([[International Nonproprietary Name|INN]]) or '''proparacaine''' ([[United States Adopted Name|USAN]]) is a [[topical anesthetic]] drug of the [[Local_anesthetic#Esters|aminoester]] group.

==Clinical pharmacology==
{{Empty section|date=June 2011}}

==Indications and usage==
Proxymetacaine hydrochloride ophthalmic solution ([[eye drop]]s) is indicated for procedures such as [[tonometry]], [[gonioscopy]], removal of [[Foreign body|foreign bodies]], or other similar procedures requiring topical anesthesia of the [[cornea]] and [[conjunctiva]].

==Warnings==
Proxymetacaine is for topical ophthalmic use only, and it is specifically not intended for injection. Prolonged use of this or any other topical ocular anesthetic may produce permanent corneal opacification with accompanying [[Vision loss|visual loss]].

==Mechanism of action==
Proxymetacaine is believed to act as an [[Receptor antagonist|antagonist]] on voltage-gated [[sodium channel]]s to affect the permeability of neuronal membranes; how this inhibits pain sensations and the exact mechanism of action of proxymetacaine are, however, unknown.

==How supplied==
Proxymetacaine is available as its hydrochloride salt in ophthalmic solutions at a concentration of 0.5%. Although it is no longer on patent, it is still marketed under the [[trade name]]s Alcaine, Ak-Taine, and others.  Proparacaine 0.5% is marketed as Poencaina by Poen Laboratories.

{{Local anesthetics}}

[[Category:Local anesthetics]]
[[Category:Benzoates]]
[[Category:Anilines]]
[[Category:Phenol ethers]]


{{nervous-system-drug-stub}}